← 返回

病例报告:接受免疫治疗的浸润性小叶癌并发子宫癌肉瘤特殊表现中的免疫与分子图谱特征

英文原题:Case report: Characterization of the immunologic and molecular landscape in a unique presentation of invasive lobular carcinoma with concurrent uterine carcinosarcoma treated with immunotherapy.

查看英文原题

Case report: Characterization of the immunologic and molecular landscape in a unique presentation of invasive lobular carcinoma with concurrent uterine carcinosarcoma treated with immunotherapy.

PubMed 2024/07/15(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

浸润性小叶乳腺癌(ILC)具有较高的晚期复发风险和独特转移模式,较易转移至妇科器官和腹膜。本文报告一例罕见病例:复发性ILC转移至腹膜,同时累及子宫肌层和宫颈。治疗过程中又发现患者并发子宫癌肉瘤,使病情处理更为复杂。患者接受激素治疗控制转移性ILC,同时接受化疗联合免疫治疗子宫癌肉瘤,疗效良好。分子检测发现,ILC具有特征性CDH1突变,子宫癌肉瘤则存在PIK3CA突变;两种突变均与上皮-间质转化有关。肿瘤免疫微环境分析发现细胞毒性NK细胞比例较高。这种显著免疫浸润可能提示该肿瘤对免疫治疗产生应答,也可能是乳腺癌转移至子宫所致。本病例报告描述了转移性ILC合并子宫癌肉瘤病例的分子和免疫学图谱。

展开英文摘要原文

Invasive lobular breast cancer (ILC) is characterized by a relatively high risk for late recurrence and a unique metastatic pattern with an increased risk for metastasis to gynecologic organs and peritoneum.

We present a unique case of recurrent ILC with metastasis to the abdominal peritoneum as well as the uterine myometrium and cervix. Treatment was complicated by the discovery of concomitant uterine carcinosarcoma. This patient was effectively treated with a combination of hormonal therapy for her metastatic ILC and a combination of chemotherapy and immunotherapy for uterine carcinosarcoma. Molecular evaluation revealed a characteristic CDH1 mutation within the ILC and a PI3KCA mutation within the uterine carcinosarcoma, both of which have been linked to epithelial-to-mesenchymal transitions.

Examination of the tumor immune microenvironment revealed proportionally more cytotoxic NK cells. This robust immune infiltration may be an indicator of the response to immunotherapy observed in this tumor or a result of the metastatic breast cancer within the uterus. This report provides a characterization of the molecular and immunologic landscape in this case with metastatic ILC and uterine carcinosarcoma.

论文信息

作者
Riedinger CJ、Eisele CD、Esnakula A、Stover DG、Freud AG、Cosgrove CM
单位
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, United States.United States
文献类型
病例报告
期刊
Frontiers in immunology2024
原文标识
PubMed 39076998 · DOI 10.3389/fimmu.2024.1422342